Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573417 | 0.83 | BACE1 (0.49) | BACE1ALDH1A1RAB9ANPC1POLB | |
| SCHEMBL13516021 | 0.82 | BACE1 (0.49) | BACE1CES2CES1HCAR2MEN1 | |
| SCHEMBL13516362 | 0.80 | BACE1 (0.47) | BACE1HCAR2KMT2AHCAR3 | |
| SCHEMBL6546743 | 0.79 | BACE1 (0.46) | BACE1GAAALDH1A1ALOX15RAB9A | |
| SCHEMBL8323836 | 0.77 | BACE1 (0.65) | BACE1ALDH1A1ALOX15SMN1; SMN2RAB9A | |
| SCHEMBL18618230 | 0.77 | ALDH1A1 (0.45) | BACE1ALDH1A1MAPT | |
| SCHEMBL3562787 | 0.76 | BACE1 (0.46) | BACE1ALDH1A1HCAR2HCAR3 | |
| SCHEMBL31048975 | 0.75 | BACE1 (0.42) | BACE1ALDH1A1SMN1; SMN2HCAR2RAB9A | |
| SCHEMBL13516448 | 0.74 | BACE1 (0.70) | BACE1CES2CES1ALDH1A1HCAR2 | |
| SCHEMBL13516583 | 0.73 | BACE1 (0.56) | BACE1CES2CES1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | disclosed |
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | LAURUS LABS LIMITED (IN) | 2020-12-31 | — | — | US | disclosed |
| US-10815202-B2 | Process for the preparation of ivacaftor | LAURUS LABS LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2019-11-14 | — | — | US | disclosed |
| WO-2017037672-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | LAURUS LABS PRIVATE LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| EP-2799437-B1 | QUINOLINE AND CINNOLINE DERIVATIVES AND USE THEREOF | UNIV SHENYANG PHARMACEUTICAL (CN) | 2016-09-14 | — | — | EP | disclosed |
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
| EP-2799437-A1 | QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2014-11-05 | — | — | EP | disclosed |
| WO-2001017977-A1 | 1,3,5-TRIAZINES AS HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | ACVR1, SLC10A2, CYP4A11 | BACE1 3252/4885CES2 3184/4885CES1 1133/4885 |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | F5, CYP4A11, ACVR1 | BACE1 3071/4885CES2 3042/4885CES1 1080/4885 |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | MET, CHEK1, KIT | BACE1 1776/4885CES2 87/4885CES1 263/4885 |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | ACVR1, SLC10A2, CYP4X1 | BACE1 2795/4885CES2 2322/4885CES1 735/4885 |
| US-10815202-B2 | Process for the preparation of ivacaftor | F5, CYP4A11, ACVR1 | BACE1 3071/4885CES2 3042/4885CES1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.